Moderna launches COVID-19 adolescent vaccine trial

By The Science Advisory Board staff writers

December 10, 2020 -- Moderna has begun a late-stage trial for a COVID-19 vaccine for adolescents between 12 and 18 years of age. The vaccine is called messenger RNA (mRNA)-1273.

The study will include 3,000 participants and is being performed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. The vaccine will be given twice, 28 days apart; each participant will receive either a placebo at each of these injections or a 100 µg dose of the vaccine. The trial will follow the study participants for 12 months after the second injection.

"Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," chief executive officer Stéphane Bancel said in a statement released by the firm.

Analysis confirms 70% efficacy rate for Oxford COVID-19 vaccine
An interim analysis of the Oxford COVID-19 vaccine (AZD1222) reports that it has an acceptable safety profile and vaccine efficacy rate of 70%. The results...
Health Canada approves emergency use for Pfizer, BioNTech's COVID-19 vaccine
Health Canada has granted authorization under an interim order for the emergency use of Pfizer-BioNTech's messenger RNA COVID-19 vaccine, BNT162b2.
Moderna to use Roche tests in COVID-19 vaccine trials
Moderna will use Roche's Elecsys anti-SARS-CoV-2 S antibody test in its messenger RNA (mRNA)-1273 vaccine research trials. The test can quantitatively...
Canada increases order for Moderna's COVID-19 vaccine
The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses,...
Moderna's COVID-19 vaccine demonstrates durable immunity in early clinical trial
Moderna published interim data from a National Institutes of Health-led phase I study of its messenger RNA (mRNA)-1273 COVID-19 vaccine on December 3...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter